Startup Seeks Nod for Inhaler to Help Smokers Quit
- Respira seeks green light from FDA for nicotine nebulizer
- Company’s CEO says new quitting methods needed for vapers
This article is for subscribers only.
As Covid-19 adds urgency to smokers’ attempts to quit, a U.S. startup says it has a new way to help them kick the habit.
Respira Technologies Inc. plans to submit an inhaler device to the Food and Drug Administration by late 2021 for authorization as nicotine replacement therapy. The nebulizer, which converts nicotine to an aerosol, aims to disrupt an estimated $618 billion market dominated by decades-old gums and patches from pharma companies as well as tobacco companies’ more recent, controversial cigarette alternatives.